Clinical Trial

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 2, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-02-14; most recent amendment 2025-04-15.
Status change: Recruiting → Terminated 2025-04-15
Status change: Not Yet Recruiting → Recruiting 2020-09-05
Trial Details
NCT Number NCT03842943
Lead Sponsor University of Louisville
Conditions Cutaneous Melanoma
Enrollment 28 participants
Start Date 2019-07-03
Primary Completion 2026-06-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-05-02